JPMorgan Chase & Co. Has $12.12 Million Stock Holdings in Organon & Co. (NYSE:OGN)

JPMorgan Chase & Co. lowered its holdings in Organon & Co. (NYSE:OGN) by 7.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 633,330 shares of the company’s stock after selling 51,627 shares during the quarter. JPMorgan Chase & Co. owned 0.25% of Organon & Co. worth $12,116,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC grew its stake in shares of Organon & Co. by 238.0% in the 3rd quarter. Barclays PLC now owns 119,483 shares of the company’s stock valued at $2,285,000 after purchasing an additional 84,136 shares during the period. Public Sector Pension Investment Board grew its position in Organon & Co. by 8.0% in the second quarter. Public Sector Pension Investment Board now owns 565,866 shares of the company’s stock valued at $11,713,000 after acquiring an additional 41,954 shares during the period. Weiss Asset Management LP acquired a new position in Organon & Co. during the third quarter worth $32,966,000. Cerity Partners LLC lifted its holdings in shares of Organon & Co. by 94.0% during the third quarter. Cerity Partners LLC now owns 667,340 shares of the company’s stock valued at $12,766,000 after acquiring an additional 323,308 shares during the period. Finally, Beddow Capital Management Inc. boosted its stake in shares of Organon & Co. by 38.8% in the 3rd quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company’s stock valued at $5,867,000 after purchasing an additional 85,775 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Down 0.7 %

Shares of NYSE OGN opened at $15.89 on Friday. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The firm’s 50-day simple moving average is $15.36 and its 200 day simple moving average is $18.39. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The company has a market cap of $4.09 billion, a price-to-earnings ratio of 3.15, a price-to-earnings-growth ratio of 0.81 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter in the previous year, the company posted $0.78 earnings per share. Organon & Co.’s revenue for the quarter was up 4.1% on a year-over-year basis. On average, research analysts expect that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were paid a $0.28 dividend. The ex-dividend date was Tuesday, November 12th. This represents a $1.12 annualized dividend and a dividend yield of 7.05%. Organon & Co.’s dividend payout ratio (DPR) is currently 22.22%.

Wall Street Analyst Weigh In

Separately, Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.